Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term hepatotoxicity of azathioprine, 6-mercaptopurine, and 6-thioguanine in inflammatory bowel disease
NL-OMON55534Phase 4Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of azathioprine, mercaptopurine and tioguanine in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (3 arms), sponsored by Vrije University Medical Center. Primary endpoint: Histologically assessed nodular regenerative hyperplasia. Started Sep 2009; status: recruiting.
02
Drugs
azathioprinemercaptopurinetioguanine
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON55534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55534.